IL303374A - Aptamers that bind to T lymphocytes - Google Patents

Aptamers that bind to T lymphocytes

Info

Publication number
IL303374A
IL303374A IL303374A IL30337423A IL303374A IL 303374 A IL303374 A IL 303374A IL 303374 A IL303374 A IL 303374A IL 30337423 A IL30337423 A IL 30337423A IL 303374 A IL303374 A IL 303374A
Authority
IL
Israel
Prior art keywords
aptamer
cell
cancer
carcinoma
seq
Prior art date
Application number
IL303374A
Other languages
English (en)
Hebrew (he)
Original Assignee
Aummune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aummune Ltd filed Critical Aummune Ltd
Publication of IL303374A publication Critical patent/IL303374A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL303374A 2020-12-03 2021-12-03 Aptamers that bind to T lymphocytes IL303374A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121080P 2020-12-03 2020-12-03
US202163257402P 2021-10-19 2021-10-19
PCT/IB2021/000849 WO2022118077A2 (en) 2020-12-03 2021-12-03 T-lymphocyte binding aptamers

Publications (1)

Publication Number Publication Date
IL303374A true IL303374A (en) 2023-08-01

Family

ID=80446452

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303374A IL303374A (en) 2020-12-03 2021-12-03 Aptamers that bind to T lymphocytes

Country Status (5)

Country Link
US (1) US12146140B2 (cg-RX-API-DMAC7.html)
EP (1) EP4256057A2 (cg-RX-API-DMAC7.html)
JP (1) JP7837345B2 (cg-RX-API-DMAC7.html)
IL (1) IL303374A (cg-RX-API-DMAC7.html)
WO (1) WO2022118077A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146140B2 (en) 2020-12-03 2024-11-19 Aummune Ltd. T-lymphocyte binding aptamers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690441A1 (en) * 2012-07-26 2014-01-29 Rheinische Friedrich-Wilhelms-Universität Bonn Method of determining a protein in a sample
US11219635B2 (en) * 2016-02-19 2022-01-11 City Of Hope Bi-specific aptamer
CN107129988A (zh) 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
WO2018017827A1 (en) 2016-07-22 2018-01-25 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific notch inhibition and related methods and compositions
WO2019035763A1 (en) 2017-08-16 2019-02-21 Agency For Science, Technology And Research APTAMERS FOR DETECTION OF ZIKA FLAVIVIRAL PROTEIN
US10584340B2 (en) * 2017-09-29 2020-03-10 University Of Florida Research Foundation, Inc. Tau protein-binding DNA aptamers with capture/detection and therapeutic utilities in tauopathy-related neurodegenerative disorders
CN113423833B (zh) 2018-09-28 2024-09-17 奥曼尼提纳米有限公司 用于选择功能性适体的方法和组合物
US20230193286A1 (en) 2020-05-20 2023-06-22 Aummune Ltd. Cytotoxic t-lymphocyte binding aptamers
US20230193285A1 (en) 2020-05-20 2023-06-22 Aummune Ltd. Bispecific personalized aptamers
US12146140B2 (en) 2020-12-03 2024-11-19 Aummune Ltd. T-lymphocyte binding aptamers

Also Published As

Publication number Publication date
JP7837345B2 (ja) 2026-03-30
WO2022118077A2 (en) 2022-06-09
EP4256057A2 (en) 2023-10-11
US20220186223A1 (en) 2022-06-16
US12146140B2 (en) 2024-11-19
WO2022118077A3 (en) 2022-09-29
JP2023553193A (ja) 2023-12-20

Similar Documents

Publication Publication Date Title
US10858658B2 (en) Compositions and methods for inhibiting gene expression of factor XII
KR102021626B1 (ko) Ngf에 대한 압타머 및 그의 용도
US20180243436A1 (en) Therapeutic cell internalizing conjugates
UA130735C2 (uk) РНКі-АГЕНТ І КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ АПОЛІПОПРОТЕЇНУ C-III (APOC3)
EP2683826B1 (en) Use of aptamers in therapy and/or diagnosis of autoimmune diseases
US20200339984A1 (en) Multivalent oligonucleotide assemblies
EP1809738B1 (en) Compositions and methods for treating hyperproliferative disorders
US20220242963A1 (en) B-cell activating cd73 antibodies
WO2016115500A1 (en) Cell penetrating antibodies
CN109069604A (zh) 新抗原组合物及其在免疫肿瘤治疗中的使用方法
CA3114302A1 (en) Methods and compositions for selection of functional aptamers
KR20180033606A (ko) 베타-ENaC-관련 질환을 치료하기 위한 유기 조성물
US20250313837A1 (en) Products and compositions
US20230193286A1 (en) Cytotoxic t-lymphocyte binding aptamers
US12146140B2 (en) T-lymphocyte binding aptamers
EP2350131A2 (en) Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
US20230193285A1 (en) Bispecific personalized aptamers
CN121532196A (zh) 半乳糖凝集素-1作为免疫检查点在制备肿瘤免疫治疗药物中的应用以及该药物
JP2022513082A (ja) 免疫応答を調節するためのIRE1α-XBP1シグナル伝達経路バイオマーカーの使用
CN117280033A (zh) T-淋巴细胞结合适体
WO2020146801A1 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growth factor
CN120456911A (zh) 用于抑制补体组分C3(C3)表达的RNAi剂、其药物组合物及使用方法
KR101753457B1 (ko) 암 줄기 유사세포 검출용 바이오마커 gpr50 및 이의 용도
Vandenbriele et al. The role of PEAR1 in platelets and Endothelial cell Biology